Rituximab and Hyaluronidase
Brand Names: Rituxan Hycela
Methodology & AI Transparency ⓘ
Rituximab and Hyaluronidase Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Federal drug listing 50242-109, 50242-108 defines Rituximab and Hyaluronidase (manufactured/labeled by Genentech, Inc.) as a prescription-only subcutaneous-route cd20-directed cytolytic antibody available in 120 mg/mL / 2000 U/mL Injection, Solution for individualized clinical regimens.
- 2 Real-world patient consensus: Zero-PHI community consensus: 93% favorable across 10 logged regimens (Rituxan Hycela).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $16.20 cash mean against $39.69 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Rituximab and Hyaluronidase include nausea (7.7%), headache (7.8%), dizziness (6.5%).
Ask our AI Specialists anything about Rituximab and Hyaluronidase
Rituximab and Hyaluronidase Mechanism, CYP450 Pathways & DailyMed Monograph
Federal drug listing 50242-109, 50242-108 defines Rituximab and Hyaluronidase (manufactured/labeled by Genentech, Inc.) as a prescription-only subcutaneous-route cd20-directed cytolytic antibody available in 120 mg/mL / 2000 U/mL Injection, Solution for individualized clinical regimens.
Clinical mechanism for Rituximab and Hyaluronidase (120 mg/mL / 2000 U/mL Injection, Solution, manufactured/labeled by Genentech, Inc.) centers on cd20-directed cytolytic antibody target modulation following subcutaneous-route uptake, maintaining therapeutic plasma exposure across FDA-listed 50242-109, 50242-108 regimens.
Following administration (120 mg/mL / 2000 U/mL Injection, Solution), Rituximab and Hyaluronidase achieves Complete (~100%) parenteral systemic delivery for Rituximab and Hyaluronidase (120 mg/mL / 2000 U/mL Injection, Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after rituximab and hyaluronidase administration onset, governed by a Mean elimination half-life of 4 to 11 hours across adult Rituximab and Hyaluronidase dosing terminal half-life through dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of rituximab and hyaluronidase.
Before initiating Rituximab and Hyaluronidase at 120 mg/mL / 2000 U/mL Injection, Solution, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to rituximab and hyaluronidase (ndc 50242-109); severe baseline organ impairment where rituximab and hyaluronidase accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on headache (7.8% of reports), nausea (7.7% of reports), dizziness (6.5% of reports).
Reconcile eGFR-adjusted medications before escalating Rituximab and Hyaluronidase in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Rituximab and Hyaluronidase maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Rituximab and Hyaluronidase (NDC 50242-109)
- Severe baseline organ impairment where Rituximab and Hyaluronidase accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (10 Reports)
Rituximab and Hyaluronidase Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Rituximab and Hyaluronidase)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden: What a 258-Participant Study Found These updated data support therapeutic similarity of CT-P10 and rituximab and support the use of CT-P10 single-drug treatment for previously untreated LTBFL. Clinical lymphoma, myeloma & leukemia • 2022-02-15 • Phase III Randomized Trial | N = 258 | 93/100 | PMID 34686445 ↗ |
| Can This Approach Help? Inside the Latest Research on Rituximab plus leflunomide in autoimmune joint pain (rheumatoid arthritis): a The primary endpoint was not reached, but rituximab + LEF demonstrated clinical benefits vs LEF in secondary endpoints. Rheumatology (Oxford, England) • 2021-11-03 • Phase III Randomized Trial | N = 93 | 88/100 | PMID 33738492 ↗ |
| Can This Approach Help? Inside the Latest Research on Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the Disease activity and treatment burden, including hospitalization and rescue treatments, remained low, indicating a potential benefit of rituximab on the long-term disease trajectory. European journal of neurology • 2025-11-15 • Phase III Randomized Trial | N = 47 | 88/100 | PMID 41194516 ↗ |
| Can This Approach Help? Inside the Latest Research on Six-year follow-up of participants in two clinical trials of rituximab or After six years, 44.1% of the cyclophosphamide group scored an SF-36 PF of at least 70, and 17.6% of at least 90, suggesting that cyclophosphamide in a subgroup may modulate the disease course in a beneficial way. PloS one • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39042627 ↗ |
| Can This Approach Help? Inside the Latest Research on Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Improved long-term efficacy with R 2 versus R-placebo and manageable safety with R 2 were observed in patients with FL, including those 70 years and older. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2026-06-15 • Phase III Randomized Trial | N = 66 | 88/100 | PMID 41990300 ↗ |
Rituximab and Hyaluronidase Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1900/unit (~$5.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $39.69 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $16.20 / mo | View logs ↓ |
Rituximab and Hyaluronidase Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Rituximab and Hyaluronidase RxNorm Concept ID | RXN-50242109-2646 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $39.69 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $16.20 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Rituximab and Hyaluronidase Patient Community, Cohort Filters & Dosage Logs
Deterministic Rituximab and Hyaluronidase reference combining NIH RxNorm (RXN-50242109-2646), Medicaid NADAC ($0.1900/unit), and anonymous cohort outcomes (93% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Rituximab and Hyaluronidase community threads and patient logs by age, biological sex, dosage, and treatment duration.